Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2026-06-18 16:30:24 ET · period of report 2026-06-16 · accession 0001104659-26-075773 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-18 16:30 | 2026-06-16 | SLS | Stergiou Angelos M. | Pres, CEO, Dir | A - Grant | $0.00 | +1.06M | 1.76M | +153% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-16 | A | A | 1,065,000 | $0.00 | 1,759,183 | D | — | — | (F1) The Reporting Person received an award of 1,065,000 restricted stock units on June 16, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date. |